Mirati Therapeutics Receives Approval from the MHRA for KRAZATI as a Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
Mirati has risen to meet one of the most challenging mutations in cancer research by developing KRAZATI, a…